A trial fibrillation (AF) is the most common sustained arrhythmia. AF produces lifestyle-limiting symptoms and increases the risk of stroke and death, 1 but current therapies have limited efficacy. The renin-angiotensin system is upregulated in cardiovascular disease, and elevated angiotensin II (Ang II) favors AF. 2,3 Ang II activates NADPH oxidase, leading to increased reactive oxygen species (ROS), and fibrillating atria are marked by increased ROS. 4,5 We recently identified the multifunctional Ca 2+ -and calmodulin-dependent protein kinase II (CaMKII) as an ROS sensor 6 and a proarrhythmic signal. 7 Oxidation of critical methionines (methionines 281/282) in the CaMKII regulatory domain locks CaMKII into a constitutively active, Ca 2+ -and calmodulin-independent conformation that is associated with cardiovascular disease. 8 On the basis of this information, we asked if oxidized CaMKII (ox-CaMKII) could be a biomarker and proarrhythmic signal for connecting increased atrial ROS to AF. We found that ox-CaMKII was increased in atrial tissue from patients with AF compared with patients in sinus rhythm and in atrial tissue from Ang II-infused compared with saline-infused mice. We used a validated mouse model of AF induction by rapid right atrial pacing 9,10 and found that mice with prior Ang II infusion were at significantly higher risk of AF compared with vehicleinfused mice. We tested AF induction in Ang II-and vehicleinfused mice with genetically engineered resistance to CaMKII oxidation by knock-in replacement of methionines 281/282 with valines in CaMKIIδ (MM-VV), the isoform associated Background-Atrial fibrillation (AF) is a growing public health problem without adequate therapies. Angiotensin II and reactive oxygen species are validated risk factors for AF in patients, but the molecular pathways connecting reactive oxygen species and AF are unknown. The Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) has recently emerged as a reactive oxygen species-activated proarrhythmic signal, so we hypothesized that oxidized CaMKIIδ could contribute to AF. Methods and Results-We found that oxidized CaMKII was increased in atria from AF patients compared with patients in sinus rhythm and from mice infused with angiotensin II compared with mice infused with saline. Angiotensin II-treated mice had increased susceptibility to AF compared with saline-treated wild-type mice, establishing angiotensin II as a risk factor for AF in mice. Knock-in mice lacking critical oxidation sites in CaMKIIδ (MM-VV) and mice with myocardiumrestricted transgenic overexpression of methionine sulfoxide reductase A, an enzyme that reduces oxidized CaMKII, were resistant to AF induction after angiotensin II infusion. Conclusions-Our studies suggest that CaMKII is a molecular signal that couples increased reactive oxygen species with AF and that therapeutic strategies to decrease oxidized CaMKII may prevent or reduce AF. (Circulation. 2013;128:1748-1757.)
with cardiovascular disease, [11] [12] [13] [14] or by myocardium-targeted antioxidant therapy by transgenic overexpression of methionine sulfoxide reductase A (MsrA), an enzyme that reduces ox-CaMKII. 15, 16 Collectively, our results support the view that Ang II promotes AF induction by increasing ROS, ox-CaM-KII, CaMKII activity, sarcoplasmic reticulum Ca 2+ leak, and delayed afterdepolarizations (DADs). Our findings provide novel insights into an ROS-and Ang II-dependent mechanism of AF by linking oxidative stress to dysfunctional intracellular Ca 2+ signaling via ox-CaMKII and identify a potential new approach for treating AF by targeted antioxidant therapy.
Methods

Human Samples and Immunodetection of ox-CaMKII
The human samples were provided by the Georg-August-University Goettingen and the University of Heidelberg after approval by the local ethics committee of the Georg-August-University Göttingen and the Medical Faculty Mannheim, University of Heidelberg (No. 2011-216 N-MA). Each patient gave written informed consent. The investigation conforms to the principles outlined in the Declaration of Helsinki. Right atrial appendage tissue samples were obtained from patients with sinus rhythm or with AF undergoing thoracotomy (Table) as published previously. 17 For immunostaining experiments, a total of 9 samples were studied, including 5 patients with sinus rhythm and 4 patients with AF (Table, middle ). For immunoblotting, a total of 51 samples were studied from 25 patients with sinus rhythm and 26 patients with AF (Table, right). We reviewed the patient charts to obtain relevant clinical information. See the online-only Data Supplement for detailed methods.
Mouse Models and Experimental Methods
All mice used in the study were available to us in C57Bl6 background. All experiments were performed in male mice 8 to 12 weeks of age. In total, we studied 262 mice. Numbers for each experimental group are provided in the figures or figure legends. See the online-only Data Supplement for detailed methods.
Statistics
Data are presented as mean±SEM. P values were assessed with a Student t test (2 tailed), ANOVA, or 2-way ANOVA, as appropriate, for continuous data. The effect of Ang II compared with saline on ox-CaMKII, CaMKII, and the ratio of ox-CaMKII to CaMKII was tested within each mouse genotype (strain) and compared among the 4 genotypes using 2-way ANOVA. The factors that were tested in the ANOVA model were genotype (wild-type [WT], MM-VV, p47 −/− , and transgenic mice with myocardium-delimited MsrA overexpression [MsrA TG]), treatment (Ang II versus saline), and genotype-treatment interaction effect. A significant genotype-treatment interaction indicated that the effect of Ang II (versus saline) differed significantly among the strains. Post hoc comparisons after ANOVA were performed with the Bonferroni test. Discrete variables were analyzed by the Fisher exact test. Statistical analyses were made with GraphPad Prism or SAS version 3.9, and the null hypothesis was rejected for values of P≤0.05. See the online-only Data Supplement for detailed methods.
Results
ox-CaMKII Is Increased in AF
Patients with AF have increased atrial CaMKII activity 18, 19 and high circulating levels of serum markers for oxidative stress. 4, 5 We first obtained right atrial tissue from patients undergoing cardiac surgery (Table) and measured ox-CaMKII using a validated antiserum against oxidized methionines 281/282 in the CaMKII regulatory domains. 6 These pilot immunofluorescence studies on atrial tissue samples made available on consent by patients with AF or normal sinus rhythm (Table, middle) showed significantly (P<0.05) higher (≈2.5 fold) ox-CaMKII levels in patients with AF ( Figure 1A and 1B) . On the basis of these initial findings, we measured ox-CaMKII in atrial tissue from a larger cohort of patients (Table, right; see also Ca channel blocker 1 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) Amiodarone 0 (0.0) 1 (3.8) in the online-only Data Supplement) in sinus rhythm (n=25) or AF (n=26) using Western blots and confirmed that AF patients have significantly elevated expression of ox-CaMKII, whereas there was no difference in total CaMKII ( Figure 1C -1F). The patient characteristics in the 2 groups (Table) were similar in terms of age, presence of hypertension and diabetes mellitus, and left ventricular ejection fraction, recognized risk factors for AF. 20 The subgroup of AF patients who were not treated with angiotensin-converting enzyme inhibitor or angiotensin receptor blockers showed the highest levels of ox-CaMKII and total CaMKII ( Figure IA and IB in the online-only Data Supplement). Taken together, these findings showed a positive association between AF and increased expression of atrial ox-CaMKII and a loss of this association in AF patients treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Ang II Treatment Enhances AF Susceptibility
To test the hypothesis that ox-CaMKII contributes to AF, we developed a mouse model of AF by infusing wild-type (WT) mice with Ang II (2000 ng•kg −1 •min −1 ) or an equal volume of normal saline via osmotic minipumps for 3 weeks. We previously established that this dose of Ang II caused a significant increase in atrial ox-CaMKII 7 and resulted in serum Ang II levels similar to those measured in heart failure patients. 21 To test whether Ang II treatment can promote AF, we performed burst pacing in the right atrium of anesthetized mice using an established method ( Figure 2A -2C). 10 Mice treated with Ang II showed significantly higher AF induction rates compared with salinetreated mice (64% [9 of 14] versus 18% [2 of 14]; P=0.018, Fisher's exact test; Figure 2D ). Ang II is known to contribute to hypertension, left ventricular hypertrophy, and heart failure, all established clinical risk factors for AF. 20 Therefore, we measured blood pressure (BP) by the tail-cuff method and assessed left ventricular size and systolic function by echocardiography. As expected, Ang II treatment significantly increased systolic BP (P<0.01; Figure 2E ) and left ventricular mass (P<0.001; Figure 2F ). Ang II-treated mice maintained a normal left ventricular ejection fraction, similar to saline-infused control mice ( Figure 2G ). These data showed that Ang II infusion increased the susceptibility of mice to AF induction by rapid right atrial pacing and established a framework for us to test the hypothesized role of ox-CaMKII in promoting AF.
ox-CaMKII Is Critical for AF
To test whether ox-CaMKII was required for AF induction in our model, we used oxidation-resistant knock-in MM-VV mice ( Figure II in the online-only Data Supplement). 22 CaMKII with the MM-VV mutation is resistant to oxidative activation but retains normal Ca 2+ -and calmodulin-dependent activation and is capable of transitioning into a Ca 2+ -and calmodulin-independent enzyme after threonine 287 autophosphorylation. 6 The MM-VV mice were significantly resistant to AF induction after Ang II infusion compared with WT Figure 3A ), suggesting that ox-CaMKII is required for increased AF susceptibility in Ang II-infused mice. WT mice treated with Ang II showed significantly higher (≈2.7 fold; 95% confidential interval, 1.4-5.1) levels of atrial ox-CaMKII compared with saline-treated mice. As expected, Ang II infusion increased ox-CaMKII less in MM-VV (≈2.1 fold; 95% confidential interval, 1.1-4.0) than in control WT ( Figure 4A and 4B) mice. When indexed to total CaMKII levels ( Figure IIIA and IIIB in the online-only Data Supplement), this increase in ox-CaMKII was much higher (≈14.2 fold; 95% confidential interval, 5.9-34.5) in Ang II-treated WT mice ( Figure 4C ). The residual increase in ox-CaMKII in the MM-VV mice likely results from expression of CaMKIIγ a myocardial CaMKII isoform not affected by the MM-VV mutation. 23 However, despite the greater increase in ox-CaMKII in WT compared with MM-VV mice, Ang II-related ROS production was increased in both WT and MM-VV mice to a similar degree ( Figure IV in the online-only Data Supplement). Interestingly, Ang II-treated WT mice showed a significant decrease in total CaMKII levels ( Figure IIIA and IIIB in the online-only Data Supplement), suggesting feedback inhibition of total CaMKII expression.
Atrial lysates from MM-VV mice showed significantly less Ca 2+ -and calmodulin-independent activity after Ang II treatment but retained WT-level CaMKII activity increases in response to isoproterenol ( Figure IIA Figure 3B ) that were similar to those of WT mice, suggesting CaMKIIδ methionine 281/282 oxidation did not affect basal BP or developmentally appropriate growth. CaMKII is known to regulate the chronotropic response to stress, and mice with CaMKII inhibition have a smaller increase in heart rate with isoproterenol treatment compared with controls. 24 Isolated Langendorff-perfused hearts from WT and MM-VV mice had similar resting heart rates ( Figure IIC in the onlineonly Data Supplement) and comparable heart rate increases after isoproterenol treatment ( Figure IID in the online-only Data Supplement), suggesting that CaMKII-dependent physiological heart rate increases do not require CaMKIIδ methionine oxidation. L-type Ca 2+ currents were similar in MM-VV and WT mice, and L-type Ca 2+ current facilitation, a CaMKII-dependent phenotype, was also preserved in MM-VV mice. 25, 26 KN-93, a small-molecule CaMKII inhibitor, 27 significantly reduced facilitation in WT and MM-VV mice ( Figure V in the online-only Data Supplement). MM-VV mice and WT controls showed similar increases in systolic BP ( Figure 3B ) and heart weight ( Figure 3C ) or left ventricular mass estimated by echocardiography after Ang II infusion ( Figure VI in the online-only Data Supplement), suggesting that ox-CaMKIIδ is dispensable for hypertensive and myocardial hypertrophic actions of Ang II. Taken together, these findings indicate that loss of methionines 281/282 in CaMKIIδ selectively reduces the proarrhythmic actions of Ang II in a pacing-induced model of AF.
NADPH Oxidase and MsrA Regulate ox-CaMKII and AF Susceptibility
Ang II increases intracellular ROS in myocardium by activating NADPH oxidase, and p47 −/− mice, 28 lacking functional NADPH oxidase, are resistant to Ang II-dependent increases in ROS and ox-CaMKII. 6 Atrial lysates from Ang II-treated p47 −/− mice did not show an increase in ox-CaMKII ( Figure 4 ), and the p47 −/− mice were also resistant to Ang II-mediated increases in AF ( Figure 3A ) but showed similar increases in BP ( Figure 3B ), overall heart weight ( Figure 3C ), and estimated left ventricular mass ( Figure VI in the onlineonly Data Supplement) after Ang II treatment compared with WT controls. ox-CaMKII is reduced by MsrA, 15 and MsrA TG mice have increased atrial MsrA protein ( Figure IIIC in the online-only Data Supplement) and are resistant to ROSinduced myocardial injury. 16 We found that Ang II-treated MsrA TG mice showed decreased AF induction compared with Ang II-treated WT mice ( Figure 3A ) and had atrial ox-CaMKII expression similar to that of saline-treated controls (Figure 4 ). The Ang II-induced increases in ROS production seen in WT atria were absent in atria from MsrA TG mice ( Figure IV in the online-only Data Supplement), suggesting that MsrA-sensitive targets represent an important component of Ang II-mediated atrial oxidation. The protection from AF in MsrA TG mice appeared to be independent of pressor effects of Ang II because MsrA TG and WT mice showed similar increases in BP ( Figure 3B ). Taken together, these findings suggest that NADPH oxidase-dependent ROS and elevated ox-CaMKII are critical for the proarrhythmic actions of Ang II in pacing-induced AF and that targeted antioxidant therapy, by MsrA overexpression, can reduce or prevent AF in Ang II-infused mice.
Ang II Increases Ca 2+ Sparks and Triggered Action Potentials
CaMKII contributes to increased sarcoplasmic reticulum Ca 2+ leak in mice with a ryanodine receptor 2 (RyR2) mutation modeled after a human arrhythmia syndrome, catecholaminergic polymorphic ventricular tachycardia, 9 in a goat model of AF and in atrial myocytes isolated from patients with AF. 18, 29 Atrial myocytes from patients with AF show increased CaMKII activity and increased CaMKII-dependent RyR phosphorylation at serine 2814. 29 Furthermore, CaMKII inhibition with KN-93 reduced the open probability of single RyR2 channels and prevented the increased frequency of sarcoplasmic reticulum Ca 2+ sparks in atrial myocardium biopsied from AF patients. 18, 29 On the basis of this knowledge, we asked whether increased RyR2 Ca 2+ leak also contributed to the mechanism of AF in WT Ang II-infused mice and measured diastolic Ca 2+ sparks, a marker of RyR2 Ca 2+ leak. 30 Atrial myocytes from Ang II-treated WT mice showed a significant (P<0.05) increase in spontaneous Ca 2+ sparks compared with atrial myocytes from saline-treated control mice ( Figure 5A and 5B). Other Ca 2+ spark parameters and sarcoplasmic reticulum Ca 2+ content were not different between the saline-and Ang II-treated WT mice ( Figure VII in the online-only Data Supplement). In contrast to findings in WT mice, the atrial myocytes isolated from Ang II-treated MM-VV mice did not show an increase in Ca 2+ sparks compared with saline-treated MM-VV mice ( Figure 5A and 5B) . A significantly greater proportion of atrial myocytes isolated from Ang II-treated WT mice showed DADs compared with atrial myocytes from saline-treated mice (P=0.03, Fisher exact test; Figure 5C and 5D). In contrast, atrial myocytes from Ang II-infused MM-VV mice did not show a significant increase in DADs compared with the atrial myocytes from saline-treated MM-VV mice. We interpret these data to suggest that the proarrhythmic effects of Ang II infusion depend on an increase in ox-CaMKII, sarcoplasmic reticulum Ca 2+ leak, and DADs.
Mice With CaMKII-Resistant RyR2 Are Protected From AF After Ang II Infusion
Enhanced CaMKII-mediated phosphorylation of serine 2814 on RyR2 is associated with an increased susceptibility to acquired arrhythmias, including AF. 31 On the basis of our findings that atrial myocytes from Ang II-infused WT mice developed more Ca 2+ sparks than atrial myocytes from salineinfused mice, we hypothesized that the proarrhythmic actions of ox-CaMKII require access to RyR2 serine 2814. We tested this hypothesis by treating mutant S2814A knock-in mice (lacking serine 2814) 9 with Ang II or saline and performing right atrial burst pacing. The S2814A mice were highly resistant to Ang II-mediated AF ( Figure 6A) . Similarly, AC3-I mice with transgenic myocardial expression of a CaMKII inhibitory peptide 32 were also resistant to the proarrhythmic effects of Ang II infusion on pacing-induced AF ( Figure 6A ). S2814A, AC3-I, and WT mice all developed similar BP increases ( Figure 6B ) and cardiac hypertrophy ( Figure 6C ) in response to Ang II, indicating that these mice were not resistant to the hemodynamic effects of Ang II but were nevertheless protected from AF.
Discussion
AF usually develops in patients with underlying structural heart disease such as left ventricular hypertrophy, coronary artery disease, valve disease, and congestive heart failure. 20 Elevated ROS is a common feature of these conditions. 33 The dose of Ang II used in our model produces a 4-fold increase in plasma Ang II compared with saline controls, 7 similar to increases in Ang II observed in heart failure patients compared with nonhypertensive control subjects. 21 Despite the extensive evidence of elevated ROS in structural heart disease, clinical trials with antioxidants have generally been unsatisfactory. [34] [35] [36] One potential obstacle to developing effective antioxidant therapies is the lack of detailed understanding of molecular pathways that are affected by ROS. The renin-angiotensin system is one of the best-understood pathways that contribute to ROS production in AF patients. 37 In the present study, we created a model of AF by infusing mice with Ang II for 3 weeks and assembled a cohort of genetically altered mice to rigorously test a novel molecular pathway that links oxidative stress to AF (Figure 7) . Our present study provides strong evidence that CaMKII is a critical ROS sensor for transducing increased ROS into enhanced AF susceptibility in mice and suggests that atrial ox-CaMKII could contribute to AF in patients.
CaMKII and increased ROS are now widely recognized to contribute to cardiac arrhythmias. 8, 38, 39 Recent studies suggest that patients with persistent AF have elevated markers of oxidative stress in serum 4 and depleted levels of atrial glutathione. 40 Under increased oxidative stress, CaMKII is activated by oxidation of methionines (methionines 281/282), 6 which lock it into a constitutively active conformation, suggesting a possible role for ox-CaMKII as an ROS-activated proarrhythmic signal in AF. 39 Our laboratory recently demonstrated that ox-CaMKII plays a major role in sinus node dysfunction, 7,22 adverse post-myocardial infarct remodeling, 6 and cardiac rupture. 16 In the present study, we investigated the role of ox-CaMKII in AF. Human atria (Figure 1 ) and Ang II-treated WT mouse atria showed significantly elevated ox-CaMKII (Figure 4 ). Atrial myocytes from Ang II-treated WT mice had a higher frequency of spontaneous Ca 2+ sparks and DADs compared with controls ( Figure 5 ). From these findings, we hypothesized that the oxidation of methionines 281/282 on CaMKIIδ causes diastolic sarcoplasmic reticulum Ca 2+ leak and DADs, cellular AF triggers. To definitively test this hypothesis, we used a recently developed knock-in mouse (MM-VV) in which CaMKIIδ, the myocardial CaMKII isoform implicated in myocardial disease, 12, 13 is resistant to oxidative activation. 22 Ang II treatment did not increase Ca 2+ -and calmodulin-independent CaMKII activity ( Figure IIA Figure 3A ). It is important to note that the MM-VV mutant form of CaMKIIδ selectively ablates the response to oxidation while retaining other aspects of CaMKII molecular physiology such as activation by Ca 2+ and calmodulin and constitutive activation by threonine 287 autophosphorylation. 6 Thus, the residual AF observed in Ang II-infused MM-VV mice could be a result of non-oxidation-dependent mechanisms for CaMKIIδ activation in our model. We found that atrial tissue from AF patients treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers did not show elevated ox-CaMKII, suggesting that Ang II stimulation oxidizes CaMKII in human atria and that ox-CaMKII-independent pathways are operative in AF patients. AF in patients is more complex than AF in our Ang II-infused mice. In particular, patients present with variable chronicity, tissue, and structural changes. In contrast, the triggers for our mice are uniform (ie, Ang II infusion and rapid right atrial pacing) and result in a similar, modest degree of hypertrophy. We interpret the data showing that an increase in ox-CaMKII in AF patients is reduced or eliminated by clinical antagonist drugs that reduce Ang II signaling as validating our findings in mice that Ang II increases ox-CaMKII. However, we suppose that the presence of AF in patients on angiotensinconverting enzyme inhibitors or angiotensin receptor blockers means that other pathways also result in AF. Our sample is not powered to ask whether AF resistance to Ang II antagonist drugs represents later-stage disease, but this is our hypothesis. Furthermore, CaMKII can be activated independently of oxidation, although oxidation appears to be the primary pathway for activating CaMKII during Ang II infusion. Thus, it is unknown whether CaMKII is also important for AF progression in the group of patients treated by Ang II antagonist drugs who exhibit normal levels of ox-CaMKII.
Although we did not see higher total CaMKII in AF patients (compared with patients in sinus rhythm), the subgroup of AF patients who were not treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers showed significantly elevated CaMKII levels, supporting prior studies that reported elevated CaMKII activity in AF. 18, 19 In contrast to the situation in patients, total CaMKII expression was reduced in mice after subacute Ang II infusion. Although the mechanism for the variable response of CaMKII expression in mice and patients is unclear, the change in CaMKII expression in mice and in humans in response to manipulation of the Ang II pathway supports the idea that CaMKII is a fundamental component of Ang II signaling. The relatively small number of patient samples is not powered for analysis of AF subtypes, but human AF may transition from paroxysmal to persistent and permanent (chronic) forms. 41 In contrast, our mouse model is simpler because it is triggered by a single upstream event (ie, Ang II infusion) and is elicited in a highly controlled environment by rapid atrial pacing. The resistance of MM-VV mice to AF provides new evidence that oxidative activation of CaMKIIδ is important for initiation of AF, whereas the finding that ox-CaMKII is elevated in atrial tissue from AF patients and particularly in AF patients naive to Ang II antagonist therapies suggests that this pathway may also participate in human AF. Thus, our findings in MM-VV mice provide strong, mechanistic evidence that ox-CaMKII plays a critical role in proarrhythmic responses to Ang II. Our studies showed that mice deficient in NADPH oxidase (p47 −/− ) and mice expressing increased MsrA are also resistant to AF ( Figure 3A ), suggesting that selectively targeted antioxidant therapies could be effective in preventing or reducing AF.
CaMKII has the potential to catalyze phosphorylation of diverse targets such as ion channels and Ca 2+ homeostatic proteins and is therefore poised to promote AF by several candidate mechanisms. 42 RyR2 serine 2814 is a validated CaMKII phosphorylation target, and multiple recent studies have shown that serine 2814 phosphorylation promotes diastolic sarcoplasmic reticulum Ca 2+ release with the potential to trigger atrial and ventricular arrhythmia, which triggers DADs, including AF. 31 Increased frequency of atrial ectopic impulses and AF are positively associated, 43 and this relationship may be important in our mouse model of Ang II infusion and pacing-induced AF. RyR2 R176Q/+ knock-in mice have diastolic sarcoplasmic reticulum Ca 2+ leak, and rapid atrial pacing increases phosphorylation of RyR2 serine 2814, leading to significantly more AF than in WT mice. 9 We found that S2814A mice were highly resistant to Ang II-mediated AF ( Figure 6A ). Our studies do not rule out a potential contribution of other CaMKII substrate proteins in AF 16, 44 but support the conclusion that RyR2 serine 2814 is an important downstream CaMKII target for proarrhythmic actions of Ang II.
Clinically, there appears to be an overlap in sinus node dysfunction and AF. [45] [46] [47] Almost half of patients enrolled in the Mode Selection Trial (MOST) with sinus node dysfunction had a history of AF, 48 but a clear mechanistic link between increased risk of AF and sinus node dysfunction is unknown. In recent studies, we showed that Ang II-and diabetes mellitus-induced CaMKII oxidation caused sinus node dysfunction by increased pacemaker cell death and fibrosis, 7 whereas MM-VV mice are resistant to sinus node dysfunction evoked by hyperglycemia. 22 Here, we provide evidence that ox-CaMKII increases the susceptibility for AF via increased diastolic sarcoplasmic reticulum Ca 2+ release, showing that the proarrhythmic actions of ox-CaMKII may occur in cardiomyocytes by increasing sarcoplasmic reticulum Ca 2+ leak or by enhanced cell death. Our findings suggest that the clinical association between sinus node dysfunction and AF might have a mechanistic basis because sinus node dysfunction and AF are downstream consequences of elevated ox-CaMKII.
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CLINICAL PERSPECTIvE
Atrial fibrillation is associated with hyperactivity of renin-angiotensin II signaling, enhanced oxidant stress, and increased activity of the multifunctional Ca 2+ and calmodulin-dependent protein kinase II (CaMKII). Excessive CaMKII activity promotes arrhythmia initiation by enhancing Ca 2+ leak from intracellular stores. We recently identified a mechanism whereby CaMKII is activated by oxidation of regulatory domain methionines in response to angiotensin II stimulation and, motivated by these findings, developed new mouse models to test the potential role of oxidation-activated CaMKII in atrial fibrillation. We identified increased oxidized CaMKII in atria from patients with atrial fibrillation compared with nonfibrillating control subjects and determined that atrial fibrillation patients treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers did not have increased atrial oxidized CaMKII. These findings suggest that CaMKII is oxidized by the renin-angiotensin II pathway and is associated with atrial fibrillation in the subgroup of patients not treated with angiotensinconverting enzyme inhibitors or angiotensin receptor blockers. Angiotensin II-infused mice also showed increased atrial oxidized CaMKII and high rates of atrial fibrillation after rapid right atrial pacing. In contrast, genetically engineered mice with oxidation-resistant CaMKII and mice with atrial overexpression of a methionine-reducing enzyme, methionine sulfoxide reductase A, were resistant to atrial fibrillation induction, intracellular Ca 2+ leak, and angiotensin II infusion-induced increases in oxidized CaMKII. These findings suggest that CaMKII is a critical component of a proarrhythmic oxidant pathway and that CaMKII inhibition could be an effective antioxidant and antiarrhythmic therapy. Mouse Models and Experimental Methods. p47 -/mice were purchased from Jackson Labs. Mice with transgenic myocardial CaMKII inhibition (AC3-I) 1 , MM-VV knock-in mice 2 and MsrA transgenic mice 3 were generated by our laboratory as described. S2814A knock-in mice were generated by the Wehrens laboratory. 4 All animal studies were reviewed and approved by the IACUC of the University of Iowa.
HR and BP measurements. One week prior to the start of each experiment, mice were trained on the tail cuff BP equipment (Visitech BP-2000 blood pressure analysis system). HR and BP recorded for four consecutive days. The readings from days 1-2 were discarded and days 3-4 were averaged for the baseline value. Saline or Ang II pumps were implanted after collecting the baseline data. HR and BP were measured for at least 4 days a week (to maintain habituation to the apparatus and handling) for 3 weeks. The last 3 days of data were averaged to assess the effect of 3 weeks of treatment. Transthoracic Echocardiography: We recorded transthoracic echocardiograms in conscious mice three weeks after Ang II pump implantation, as previously described. 6 Images were acquired and analyzed by an operator blinded to mouse genotype and treatment. (EP studies) . Mice were anesthetized with isoflurane (2% for induction and 1.5% for maintenance of anesthesia; Isotec100 Series Isoflurane Vaporizer; Harvard Apparatus). During EP studies the mouse body temperature was monitored by an intra-rectal probe and controlled using mousepad circuit board equipped with a heating element (Mousepad, THM 100, Indus Instruments, USA). All studies were performed at 37.0 ± 0.5°C. We used a Millar 1.1F octapolar EP catheter (EPR-800; Millar Instruments) inserted via the right jugular vein, as previously described. 4 Blots were washed in TBS-T and incubated with appropriate HRP-conjugated secondary antibodies. Protein bands were detected using ECL reagent (Lumi-Light, Roche), and loading was monitored by Coomassie staining of the blots after antibody probing. Atrial lysates from Ang II treated mice were run side by side on the same gel with lysates from saline treated mice from the same genotype. Quantification was performed using Image J analysis software (version 1.46, NIH).
Mini
In vivo Electrophysiology
ROS detection.
Murine left atria, acquired as described above, were mounted and flash frozen in Tissue Freezing Medium (Triangle Biomedical Sciences, Durham). The tissue was then cryo sectioned (30 μm), rinsed with PBS and 6 incubated in DHE (2 × 10 -2 M, Invitrogen) for 15 minutes at room temperature in darkness as previously described with minor alterations. 8 Fluorescence was measured using a laser scanning confocal microscope (Zeiss 510 and 710; excitation at 488 nm and detection at 585 nm by using a long-pass filter). For quantification and analysis, tissue fluorescence was corrected for the nuclear fluorescence signal and normalized to the area of the imaged tissue section using Image J analysis software (version 1.46, NIH).
Atrial myocyte isolation. Atrial myocytes were isolated from adult mouse hearts using an established protocol with minor modifications. 9
Voltage clamp. Voltage and current signals were measured with an Axon 200B
patch-clamp amplifier controlled by a personal computer using a Digidata 1320A acquisition board driven by pClamp 8.0 (Axon Instruments). We used perforated (amphotericin B) patch for I Ca and action potential studies. 10 All experiments were conducted at T=35°C. Recording pipettes, fabricated from borosilicate glass, had tip diameters of 2-3 μm and resistance of 2-4 MΩ, when filled with recording solution. All solutions were adjusted to 275-295 mOsm. Ca 2+ Imaging. Calcium imaging was performed as described previously. 11 Briefly, atrial myocytes were loaded with Fluo-3 AM (5 μM, 20 min) at room temperature. After de-esterification, the cells will be perfused with normal Tyrode solution (1.8 mM Ca 2+ ). Confocal Ca 2+ imaging will be performed with a laser scanning confocal microscope (LSM 510 Meta, Carl Zeiss) equipped with a NA=1.35, 63x lens. Line-scan measurement of Ca 2+ transients, SR content and sparks were acquired at a sampling rate of 1.93 ms/line along the longitudinal
